In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated
with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m 2 day 1 …

The Clinical Trials Group of the National Cancer Institute of Canada (NCIC) studied single-
agent epirubicin in 40 previously untreated patients with extensive small-cell lung cancer …

Small cell lung cancer (SCLC) accounts for 20% to 25% of all lung cancer cases in
developing countries. The incidence of and mortality from SCLC continues to increase in …

Seventy-eight patients with evaluable small-cell lung cancer (SCLC) were treated with
etoposide (VP-16) and cisplatin after their disease failed to respond to, or relapsed after …

Thirty‐seven patients with small cell carcinoma of the lung and no prior chemotherapy were
treated with a program involving the alternation of two three‐drug regimens, each composed …

One hundred and forty-five patients with limited stage small cell lung cancer were included
in a randomized trial to evaluate the effect of chemotherapy with or without chest irradiation …

Small cell lung cancer is an aggressive tumor characterized by genetic complexity, rapid
doubling time, and early development of disseminated disease. Unfortunately, few …

BACKGROUND Paclitaxel is an active agent in the initial treatment of patients with small cell
lung carcinoma. The authors evaluated the toxicity and efficacy of paclitaxel (1‐hour …

Purpose: This study was designed to determine the efficacy and toxicity of cisplatin,
etoposide, and paclitaxel (PET) in patients with extensive-stage small cell lung cancer (ES …

Many studies in small cell carcinoma of the lung (SCCL) have demonstrated a high
response rate and a potential for cure in a subset of patients. Combination chemotherapy …